SoftOx names Dr. Bruce Montgomery to chair Clinical Advisory Board

PUBT · 2d ago
SoftOx names Dr. Bruce Montgomery to chair Clinical Advisory Board
  • SoftOx appointed Dr. A. Bruce Montgomery to establish and chair its Clinical Advisory Board ahead of a planned Phase 2b SIS study.
  • Board mandate includes advising on Phase 2b dose-ranging design for chronic pulmonary infection, with cystic fibrosis expected as lead indication.
  • Montgomery previously led R&D at PathoGenesis, steering TOBI to FDA approval, later founded Corus Pharma, later led CAYSTON development at Gilead.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SoftOx Solutions AS published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202609290319OSLOBORSNEWS__EN_F243ED079D1CC8952992D45BB31DBE4), on September 29, 2026, and is solely responsible for the information contained therein.